The present invention relates to glucagon-like peptide-1 (GLP-1) receptor agonists (which include macromolecular agonists such as GLP-1 and the derivatives thereof and exendins and the derivatives thereof, and micromolecular agonists such as geniposide) for treating diseases which can be treated by activating GLP-1 receptors in the central nervous system, including in the spinal cord, such as pain, especially chronic pain including neuropathic pain, tumour pain, diabetes pain, immune inflammatory pain, lower back pain and the like.
GLP-1 RECEPTOR AGONIST FOR TREATING PAIN